Literature DB >> 20082634

Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action.

Jamal Tazi1, Nadia Bakkour, Virginie Marchand, Lilia Ayadi, Amina Aboufirassi, Christiane Branlant.   

Abstract

The retroviral life cycle requires that significant amounts of RNA remain unspliced and perform several functions in the cytoplasm. Thus, the full-length RNA serves both the viral genetic material that will be encapsulated in viral particles and the mRNA encoding structural and enzymatic proteins required for viral replication. Simple retroviruses produce one single-spliced env RNA from the full-length precursor RNA, whereas complex retroviruses, such as HIV, are characterized by the production of multiple-spliced RNA species. In this review we will summarize the current acknowledge about the HIV-1 alternative splicing mechanism and will describe how this malleable process can help further understanding of infection, spread and dissemination through splicing regulation. Such studies coupled with the testing of splicing inhibitors should help the development of new therapeutic antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082634     DOI: 10.1111/j.1742-4658.2009.07522.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  43 in total

1.  Driving factors in amiloride recognition of HIV RNA targets.

Authors:  Neeraj N Patwardhan; Zhengguo Cai; Aline Umuhire Juru; Amanda E Hargrove
Journal:  Org Biomol Chem       Date:  2019-10-30       Impact factor: 3.876

Review 2.  Idiosyncrasies of hnRNP A1-RNA recognition: Can binding mode influence function.

Authors:  Jeffrey D Levengood; Blanton S Tolbert
Journal:  Semin Cell Dev Biol       Date:  2018-04-09       Impact factor: 7.727

3.  Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.

Authors:  Didier Scherrer; Regine Rouzier; Marine Cardona; P Noel Barrett; Jean-Marc Steens; Paul Gineste; Robert L Murphy; Jamal Tazi; Hartmut J Ehrlich
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 4.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

Review 5.  Human Papillomavirus E2 Protein: Linking Replication, Transcription, and RNA Processing.

Authors:  Sheila V Graham
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

6.  Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Authors:  David J Schnepple; Brett Shepard; Gary D Bren; Nathan W Cummins; Sekar Natesampillai; Sergey Trushin; Alicia Algeciras-Schimnich; Xue W Meng; Amy M Sainski; Stacey A Rizza; Scott H Kaufmann; Andrew D Badley
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

7.  Models for predicting effective HIV chemoprevention in women.

Authors:  Melanie R Nicol; Cindi W Emerson; Heather M A Prince; Julie A E Nelson; Yuri Fedoriw; Craig Sykes; Elizabeth J Geller; Kristine B Patterson; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

8.  Natural single-nucleotide polymorphisms in the 3' region of the HIV-1 pol gene modulate viral replication ability.

Authors:  Masako Nomaguchi; Ariko Miyake; Naoya Doi; Sachi Fujiwara; Yasuyuki Miyazaki; Yasuko Tsunetsugu-Yokota; Masaru Yokoyama; Hironori Sato; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

9.  Stably integrated and expressed retroviral sequences can influence nuclear location and chromatin condensation of the integration locus.

Authors:  Jens Nagel; Birgit Gross; Manja Meggendorfer; Carolin Preiss; Manuel Grez; Ruth Brack-Werner; Steffen Dietzel
Journal:  Chromosoma       Date:  2012-03-14       Impact factor: 4.316

10.  Alternative splicing regulated by butyrate in bovine epithelial cells.

Authors:  Sitao Wu; Congjun Li; Wen Huang; Weizhong Li; Robert W Li
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.